CTIS2024-513027-16-00招募中1 期
Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable mucosal melanoma (IMMUQ) - 2017/2558
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Be willing and able to provide written informed consent/assent for the trial., 10. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required., 11. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year., 12. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy., 13. Patient affiliated to a social security system or beneficiary of the same, 14. Not having any contraindication for lenvatinib treatment, 2. Be >18 years of age on day of signing informed consent., 3. Present with a resectable mucosal melanoma., 4. Be eligible for surgical treatment (without any contraindications)., 5. Be eligible for adjuvant radiotherapy., 6. Have measurable disease based on RECIST 1.1., 7. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor., 8. Have a performance status of 0 or 1 on the ECOG Performance Scale., 9. Demonstrate adequate organ function as defined in table 1, all screening labs should be performed within 10 days of treatment initiation.
排除标准
- •1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment., 10. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability., 11. Has active autoimmune and/or immune mediated inflammatory disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment., 12. Has known history of, or any evidence of active, non-infectious pneumonitis., 13. Has an active infection requiring systemic therapy., 14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator., 15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial., 16. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment., 17. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent., 18. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)., 19. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)., 2. Has a metastatic disease., 20. Has received a live vaccine within 30 days of planned start of study therapy., 21. Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing, 22. Has a prior history of organ transplant including allogeneic stem cell transplant, 23. Has a LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO), 24. Has an uveal melanoma, For the cohort B, patients must be excluded if one of the following additional criteria is met : 25. Uncontrolled blood pressure (Systolic BP>140 mmHg or diastolic BP >90 mmHg) in spite of an optimized regimen of antihypertensive medication, 26. Electrolyte abnormalities that have not been corrected, 27. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 12 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening, 28. Bleeding or thrombotic disorders or subjects at risk for severe he
研究者
相似试验
进行中（未招募）
1 期
Study assessing if a chemotherapy drug called Cabazitaxel is effective in Patients with certain type of breast cancer (HER2 negative) that has spread to brain that is un treatable.Her-2 negative breast cancer with brain metastasesMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000542-35-GBThe Clatterbridge Cancer Centre NHS Foundation Trust19
已完成
2 期
Efficacy of cabazitaxel in patients with HER2-negative metastatic breast cancerPatients with HER2-negative metastatic breast cancer and having unresectable brain metastases.Malignant neoplasm of breastCancerISRCTN79877830The Clatterbridge Cancer Centre NHS Foundation Trust (UK)19
招募中
不适用
A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase.Chronic Myeloid LeukemiaJPRN-UMIN000005843Epidemiological and Clinical Research Information Network (ECRIN)30
进行中（未招募）
不适用
Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed lymphoma patients. - BeEAMDiagnosis of Non-Hodgkin lymphoma of any subtype, chronic lymphocytic leukemia, or Hodgkin disease either refractory or relapsed after at least one line of chemotherapy.MedDRA version: 9.1Level: HLGTClassification code 10025320MedDRA version: 9.1Level: HLGTClassification code 10025319EUCTR2008-002736-15-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
进行中（未招募）
不适用
study to evaluate the efficacy of a preparative regimen for transplantation in refractory/relapsed non-Hodgkin lymphoma patients.Adult agressive B-cell non-Hodgkin lymphoma patients.MedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10012821Term: Diffuse large B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001246-14-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE